Warm autoimmune haemolytic anaemia (warm AIHA; IgG-mediated autoimmune haemolysis)
Haemolytic anaemia · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
IgG autoantibodies (optimal at 37 C) coat red cells -> extravascular splenic destruction. Primary or secondary (lymphoma/CLL, SLE, drugs, infection). Presents with rapid anaemia, jaundice, splenomegaly. Steroids are first-line. Transfuse for life-threatening anaemia despite cross-match difficulty - do not withhold.
Red flags
- Rapidly falling Hb with angina, dyspnoea, altered mentation (critical anaemia)
- Haemoglobinuria / acute kidney injury
- Features of underlying lymphoma/CLL (lymphadenopathy, B symptoms)
- Concurrent thrombocytopenia (Evans syndrome) with bleeding
- Signs suggesting TTP (fever, neuro, renal, schistocytes) - different, urgent pathway
Assessment
Differential diagnosis
- Cold agglutinin disease / paroxysmal cold haemoglobinuria (cold AIHA)
- Hereditary haemolysis (G6PD, spherocytosis, sickle)
- Microangiopathic haemolysis (TTP/HUS/DIC) - needs blood film
- Drug-induced immune haemolysis
- Evans syndrome (AIHA + ITP)
- Hypersplenism, mechanical valve haemolysis
Investigations
- Direct antiglobulin test (DAT/Coombs): IgG +/- C3d positive (warm pattern)
- FBC + reticulocytes (raised), blood film (spherocytes, polychromasia, agglutination)
- Haemolysis screen: unconjugated bilirubin up, LDH up, haptoglobin down, urinary urobilinogen/haemoglobinuria
- Group & screen - warn lab (autoantibody complicates cross-match; need extended phenotype)
- Screen for secondary cause: SLE serology, CT/LDH/paraprotein for lymphoproliferative, viral serology, drug history
- G6PD if differential unclear
Management
- Confirm haemolysis + warm DAT pattern; exclude microangiopathy on film (do NOT miss TTP)
- Start corticosteroids - first-line for warm AIHA
- Folic acid supplementation (ongoing haemolysis consumes folate)
- Transfuse if symptomatic/life-threatening anaemia - give least-incompatible / best-match units, do not delay for perfect cross-match; transfuse slowly with monitoring
- Identify and treat/stop secondary cause (drug, underlying lymphoproliferative or autoimmune disease)
- Add rituximab early if severe or steroid-refractory; consider IVIG as temporising measure
- VTE prophylaxis - active haemolysis is prothrombotic
- If refractory: splenectomy (ensure vaccination) or other immunosuppression per haematology
Drugs & doses
Prednisolone 1 mg/kg PO once daily (typical 60-100 mg) until Hb recovers, then slow taper over weeks-months [verify local dose]
Methylprednisolone 100-250 mg IV daily for severe/fulminant haemolysis [verify local dose]
Folic acid 5 mg PO once daily
Rituximab 375 mg/m2 IV weekly x4 (or 1000 mg x2) for steroid-refractory/relapsing disease [verify local dose]
IVIG 0.4 g/kg/day IV x5 days - temporising only, less effective than in ITP [verify local dose]
Transfuse packed red cells - least incompatible units, warmed, slow with close monitoring
Disposition
Admit under medicine/haematology for significant symptomatic anaemia. Critical anaemia or cardiorespiratory compromise -> HDU. Haematology-led immunosuppression and workup for secondary cause.
Complications & pitfalls
- High-output cardiac failure from severe anaemia
- Venous/arterial thromboembolism
- Steroid complications, infection on immunosuppression
- Relapse / chronic transfusion dependence
- Post-splenectomy sepsis
Exam pearls
- Transfusion is NOT contraindicated - 'least incompatible' blood saves lives; liaise with transfusion lab early
- Always look for a secondary cause - new warm AIHA in an older patient may be the first sign of CLL/lymphoma
- Spherocytes on film + positive DAT distinguishes AIHA from hereditary spherocytosis (DAT negative)
- Folate replacement often forgotten in brisk haemolysis
- Rituximab now used early as steroid-sparing agent
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.